ReviewCancer cell international2025
Targeting cuproptosis for treatment and prognostic assessment in endometrial cancer.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Endometrial Cancer is a prevalent malignant tumor in gynecology, marked by high incidence and poor prognosis. The discovery of cuproptosis, a copper-dependent cell death pathway, offers new therapeutic potential. We systematically reviewed literature on cuproptosis mechanisms in endometrial cancer, including copper metabolism dysregulation, prognostic biomarkers, and therapeutic strategies. Then we identified three key findings: (1) Copper homeostasis disruption promotes cancer via angiogenesis, metastasis, and chemoresistance; (2) Cyclin-dependent kinase inhibitor 2 A and glutaminase exhibit strong prognostic predictive value; (3) The strategy of regulating copper homeostasis exhibits anticancer effects. Cuproptosis targeting represents a promising strategy for endometrial cancer management. Further clinical validation of cuproptosis-related biomarkers and optimization of combination therapies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.